|Articles|June 6, 2013
From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us
5